الفهرس 
introductionOnly 14 pages are availabe for public view
 |  | from | 189 |  |  |
| | | from | 189 | | |
Abstract
cyclosporin A (CsA), a unique fungal-origin lipophilic cyclic polypeptide, was licensed for clinical usage. It boosts renal and extrarenal transplant survival as well as acute rejection rates and is commonly used to treat some autoimmune diseases, such as rheumatoid arthritis, inflammatory bowel disease. The current study sought to discover the mechanisms underlying pyrvinium pamoate and niclosamide hepatoprotective efficacy against hepatotoxicity induced by cyclosporin A. Present data show that niclosamide and pyrvinium pamoate represent a viable approach to protect the liver against toxicity-induced by cyclosporin A through inhibiting oxidative stress, inflammation, Wnt/β-catenin signaling and apoptosis thus conserving liver function.